ATE404221T1 - Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen - Google Patents

Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen

Info

Publication number
ATE404221T1
ATE404221T1 AT99928448T AT99928448T ATE404221T1 AT E404221 T1 ATE404221 T1 AT E404221T1 AT 99928448 T AT99928448 T AT 99928448T AT 99928448 T AT99928448 T AT 99928448T AT E404221 T1 ATE404221 T1 AT E404221T1
Authority
AT
Austria
Prior art keywords
inflammatory bowel
bowel disease
treating inflammatory
preventing
antibodies against
Prior art date
Application number
AT99928448T
Other languages
English (en)
Inventor
John Kink
Katherine Worledge
Douglas Stafford
Original Assignee
Ophidian Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophidian Pharm Inc filed Critical Ophidian Pharm Inc
Application granted granted Critical
Publication of ATE404221T1 publication Critical patent/ATE404221T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99928448T 1998-06-10 1999-06-07 Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen ATE404221T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/095,535 US6395273B1 (en) 1998-06-10 1998-06-10 Prevention and treatment of inflammatory bowel disease
US09/325,825 US6663864B1 (en) 1998-06-10 1999-06-04 Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE404221T1 true ATE404221T1 (de) 2008-08-15

Family

ID=22252452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928448T ATE404221T1 (de) 1998-06-10 1999-06-07 Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen

Country Status (5)

Country Link
US (3) US6395273B1 (de)
EP (1) EP2033658A1 (de)
AT (1) ATE404221T1 (de)
CA (1) CA2334471A1 (de)
DE (1) DE69939316D1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
EP1885755A4 (de) 2005-05-05 2009-07-29 Univ Duke Cd19-antikörper-therapie für autoimmunerkrankungen
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
EP2215474A4 (de) * 2007-07-16 2012-07-18 Avaxia Biologics Inc Antikörpertherapie zur modulation der funktion von darmrezeptoren
EP2725035A1 (de) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antikörpertherapie zur Verwendung im Verdauungstrakt
US9566297B2 (en) * 2009-02-17 2017-02-14 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
EP3831407A1 (de) * 2009-04-08 2021-06-09 LipUm AB Neue verfahren zur behandlung von entzündungserkrankungen
EP2461818B1 (de) 2009-08-03 2018-10-17 Incube Labs, Llc Schluckbare kapsel und verfahren zur stimulation der inkretinproduktion im darmtrakt
PL2488202T3 (pl) * 2009-10-15 2015-12-31 Avaxia Biologics Inc Przeciwciała terapeutyczne o aktywności miejscowej w przewodzie pokarmowym
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8609098B2 (en) * 2010-06-10 2013-12-17 Adbiotech Co., Ltd. Composition for repression of hyperlipidemia and obesity through suppression of intestinal cholesterol absorption
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
CA3038602C (en) 2015-09-29 2023-12-05 ProdrugXtend Pty Ltd Extended-release formulations comprising 6-thioguanine
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
EP3735421A4 (de) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. Verfahren zur behandlung von il-6-vermittelter entzündung ohne immunsuppression
GB201812262D0 (en) * 2018-07-27 2018-09-12 Micropharm Ltd Therapies for treating proctitis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477432A (en) 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
EP0155549B1 (de) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. DNS den menschlichen Tumornekrosisfaktor kodierend und das menschliche Tumornekronisfaktor-Polypeptid
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0368367A1 (de) 1984-12-21 1990-05-16 Biogen, Inc. Reinigung, Herstellung und Verwendung von Tumornekrosefaktoren
GB8519848D0 (en) 1985-08-07 1985-09-11 Schweiz Rotes Kreuz Treatment of chronic inflammatory disease
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
ES2052496T3 (es) 1985-11-25 1994-07-16 Ghen Corp Sustancia que contiene anticuerpo especifico obtenida de huevos y metodo para su produccion y uso.
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5753228A (en) 1992-08-25 1998-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
AU2365795A (en) 1995-04-20 1996-11-07 Centocor Inc. Multiple administrations of anti-tnf antibody
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
US5772999A (en) 1996-07-30 1998-06-30 Dcv Biologics, L.P. Method of preventing, countering, or reducing NSAID-induced gastrointestinal damage by administering milk or egg products from hyperimmunized animals
NZ335170A (en) 1996-10-02 2001-08-31 Ovimmune Inc Oral administration of chicken yolk Ig-gamma antibodies to treat disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
US20050053604A1 (en) 2005-03-10
US6663864B1 (en) 2003-12-16
US7261891B2 (en) 2007-08-28
US6395273B1 (en) 2002-05-28
DE69939316D1 (de) 2008-09-25
EP2033658A1 (de) 2009-03-11
CA2334471A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
ATE404221T1 (de) Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
DE69734483D1 (de) Polynukleotid-Impfstoff, vorzugsweise zur Behandlung der Atemkrankheit bei Rindern
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE59607691D1 (de) Anordnung zur elektro-thermischen behandlung des menschlichen oder tierischen körpers
DE60143660D1 (de) Vorrichtung zur behandlung des nasen-rachenraumes
KR930702519A (ko) 동물 및 사람에서의 감염을 치료 및 예방하는 신규한 항체
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
FI943974L (fi) Kotieläinten ihotulehdusten käsittelyvesi
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
ATE326534T1 (de) Methode zur behandlung von muskelkrankheiten
DE69214690D1 (de) Vorrichtung für die Wäsche, aus therapeutischen oder hygienischen Gründen, von menschlichen oder tierischen internen Leitungen
DE50014268D1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
DE68909465D1 (de) Behandlung von pferdeviehbestand.
ATE374037T1 (de) Pimenta-extrakt enthaltende zusammensetzung in behandlungsverfahren für wassertiere
FR2676622B1 (fr) Prothese capillaire et procede de traitement des calvities au moyen de cette prothese.
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
DE3765916D1 (de) Sonde zur einfuehrung in den verdauungs- oder ausscheidungstrakt des menschlichen oder tierischen koerpers, insbesondere lithotriptor-sonde.
JPS5319668A (en) Treating of excrement of cattle and pig by using water sprinkled filtering bed comprising ceramic stones
NO304631B1 (no) FremgangsmÕte for fremstilling av overflatekoagulert for til kjµledyr, oppdrettsfisk pelsdyr fugler og andre dyr ved overflatekoagulering

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties